GlassScriptPhysician profile
Jennifer A Martinez
NPI 1356723217
$7,627.86
in general payments reported to CMS, 2019-2025
44 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,568 · 2022: $1,641 · 2023: $1,476 · 2024: $1,934 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,418.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,744.76 | 2021-2025 | |
| Ucb, INC. | $744.07 | 2021-2025 | Briviact, Rystiggo, Nayzilam |
| Sk Life Science, INC. | $454.81 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $397.11 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $381.95 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $353.39 | 2021-2024 | Ingrezza, Ongentys |
| Lilly USA, LLC | $332.18 | 2021-2024 | Emgality, Reyvow |
| Argenx US, INC. | $321.08 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $315.94 | 2021-2025 | |
| Amgen INC. | $261.39 | 2021-2024 | Aimovig |
| Eisai INC. | $219.84 | 2022-2025 | |
| Novo Nordisk INC | $167.34 | 2022-2024 | Wegovy |
| Neurelis, INC. | $163.85 | 2021-2023 | Valtoco |
| Biohaven Pharmaceutical Holding Company LTD. | $160.29 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $118.61 | 2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.